| Year |
Citation |
Score |
| 2024 |
Pai CP, Wang H, Seachrist DD, Agarwal N, Adams JA, Liu Z, Keri RA, Cao K, Schiemann WP, Kao HY. The PML1-WDR5 axis regulates H3K4me3 marks and promotes stemness of estrogen receptor-positive breast cancer. Cell Death and Differentiation. PMID 38627584 DOI: 10.1038/s41418-024-01294-6 |
0.542 |
|
| 2023 |
Caputo A, Vipparthi K, Bazeley P, Downs-Kelly E, McIntire P, Duckworth LA, Ni Y, Hu B, Keri RA, Karaayvaz M. Spatial transcriptomics suggests that alterations occur in the preneoplastic breast microenvironment of BRCA1/2 mutation carriers. Molecular Cancer Research : McR. PMID 37878345 DOI: 10.1158/1541-7786.MCR-23-0489 |
0.409 |
|
| 2023 |
Kao HY, Pai CP, Wang H, Agarwal N, Adams J, Liu Z, Seachrist D, Keri R, Schiemann W. The PML1-WDR5 axis regulates H3K4me3 marks and promotes stemness of estrogen receptor-positive breast cancer. Research Square. PMID 37720048 DOI: 10.21203/rs.3.rs-3266720/v1 |
0.544 |
|
| 2023 |
Bobbitt JR, Seachrist D, Keri RA. Chromatin organization and transcriptional programming of breast cancer cell identity. Endocrinology. PMID 37394919 DOI: 10.1210/endocr/bqad100 |
0.459 |
|
| 2023 |
Caputo A, Vipparthi K, Bazeley P, Downs-Kelly E, McIntire P, Ni Y, Hu B, Keri RA, Karaayvaz M. Alterations in the preneoplastic breast microenvironment of mutation carriers revealed by spatial transcriptomics. Biorxiv : the Preprint Server For Biology. PMID 37292816 DOI: 10.1101/2023.05.24.542078 |
0.413 |
|
| 2023 |
Anstine LJ, Majmudar PR, Aponte A, Singh S, Zhao R, Weber Bonk KL, Abdul-Karim FW, Valentine M, Seachrist DD, Grenell-Nickelson KE, Cuellar-Vite L, Sizemore GM, Sizemore ST, Webb BM, Thompson CL, ... Keri RA, et al. TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis. Cancer Research. PMID 36696357 DOI: 10.1158/0008-5472.CAN-22-3133 |
0.504 |
|
| 2022 |
Cuellar-Vite L, Weber-Bonk KL, Abdul-Karim FW, Booth CN, Keri RA. Focal Adhesion Kinase Provides a Collateral Vulnerability That Can Be Leveraged to Improve mTORC1 Inhibitor Efficacy. Cancers. 14. PMID 35884439 DOI: 10.3390/cancers14143374 |
0.569 |
|
| 2021 |
Seachrist DD, Anstine LJ, Keri RA. FOXA1: A Pioneer of Nuclear Receptor Action in Breast Cancer. Cancers. 13. PMID 34680352 DOI: 10.3390/cancers13205205 |
0.451 |
|
| 2021 |
Piemonte KM, Anstine LJ, Keri RA. Centrosome Aberrations as Drivers of Chromosomal Instability in Breast Cancer. Endocrinology. 162. PMID 34606589 DOI: 10.1210/endocr/bqab208 |
0.425 |
|
| 2021 |
Webb BM, Bryson BL, Williams-Medina E, Bobbitt JR, Seachrist DD, Anstine LJ, Keri RA. TGF-β/Activin Signaling Promotes CDK7 Inhibitor Resistance in Triple Negative Breast Cancer Cells through Upregulation of Multidrug Transporters. The Journal of Biological Chemistry. 101162. PMID 34481843 DOI: 10.1016/j.jbc.2021.101162 |
0.326 |
|
| 2021 |
Adorno-Cruz V, Hoffmann AD, Liu X, Dashzeveg NK, Taftaf R, Wray B, Keri RA, Liu H. promotes expression of and in enhancing breast cancer stemness and metastasis. Genes & Diseases. 8: 493-508. PMID 34179312 DOI: 10.1016/j.gendis.2020.01.015 |
0.508 |
|
| 2020 |
Sahni JM, Gayle SS, Bonk KLW, Vite LC, Yori JL, Webb B, Ramos EK, Seachrist DD, Landis MD, Chang JC, Bradner JE, Keri RA. Correction: Bromodomain and extraterminal protein inhibition blocks growth of triple-negative breast cancers through the suppression of aurora kinases. The Journal of Biological Chemistry. 295: 9266. PMID 33516519 DOI: 10.1074/jbc.AAC120.014699 |
0.811 |
|
| 2020 |
Sahni JM, Gayle SS, Bonk KLW, Vite LC, Yori JL, Webb B, Ramos EK, Seachrist DD, Landis MD, Chang JC, Bradner JE, Keri RA. Correction: Bromodomain and extraterminal protein inhibition blocks growth of triple-negative breast cancers through the suppression of aurora kinases. The Journal of Biological Chemistry. 295: 9266. PMID 32620694 DOI: 10.1074/jbc.AAC120.014699 |
0.811 |
|
| 2020 |
Turaga SM, Silver DJ, Bayik D, Paouri E, Peng S, Lauko A, Alban TJ, Borjini N, Stanko S, Naik U, Keri RA, Connor JR, Barnholtz-Sloan JS, Rubin JB, Berens M, et al. JAM-A functions as a female microglial tumor suppressor in glioblastoma. Neuro-Oncology. PMID 32592484 DOI: 10.1093/Neuonc/Noaa148 |
0.434 |
|
| 2020 |
Seachrist DD, Hannigan MM, Ingles NN, Webb BM, Weber-Bonk KL, Yu P, Bebek G, Singh S, Sizemore ST, Varadan V, Licatalosi DD, Keri RA. --The transcriptional repressor BCL11A promotes breast cancer metastasis. The Journal of Biological Chemistry. PMID 32576660 DOI: 10.1074/Jbc.Ra120.014018 |
0.527 |
|
| 2020 |
Roberts MS, Anstine LJ, Finke VS, Bryson BL, Webb BM, Weber-Bonk KL, Seachrist DD, Majmudar PR, Keri RA. KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene. Breast Cancer Research : Bcr. 22: 66. PMID 32552913 DOI: 10.1186/S13058-020-01305-7 |
0.48 |
|
| 2020 |
Roberts MS, Sahni JM, Schrock MS, Piemonte KM, Weber-Bonk KL, Seachrist DD, Avril S, Anstine LJ, Singh S, Sizemore ST, Varadan V, Summers MK, Keri RA. LIN9 and NEK2 are core regulators of mitotic fidelity that can be therapeutically targeted to overcome taxane resistance. Cancer Research. PMID 32054769 DOI: 10.1158/0008-5472.Can-19-3466 |
0.458 |
|
| 2020 |
Adorno-Cruz V, Hoffmann A, Liu X, Keri R, Liu H. Abstract P3-02-15: Integrin a2 promotes stemness and lung metastasis in triple negative breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P3-02-15 |
0.565 |
|
| 2020 |
Webb BM, Shively M, Piemonte K, Sahni JM, Keri RA. Abstract P2-04-01: Cyclin dependent kinase 7 ( CDK7) inhibition promotes genomic instability and mitotic catastrophe in triple negative breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P2-04-01 |
0.558 |
|
| 2020 |
Adorno-Cruz V, Hoffmann AD, Liu X, Dashzeveg NK, Taftaf R, Wray B, Keri RA, Liu H. ITGA2 promotes expression of ACLY and CCND1 in enhancing breast cancer stemness and metastasis Genes and Diseases. DOI: 10.1016/J.Gendis.2020.01.015 |
0.577 |
|
| 2019 |
Shukla S, Jandzinski M, Wang C, Gong X, Bonk KW, Keri RA, Steinmetz NF. A Viral Nanoparticle Cancer Vaccine Delays Tumor Progression and Prolongs Survival in a HER2 Tumor Mouse Model. Advanced Therapeutics. 2. PMID 33855164 DOI: 10.1002/adtp.201800139 |
0.315 |
|
| 2019 |
Anstine LJ, Keri R. A new view of the mammary epithelial hierarchy and its implications for breast cancer initiation and metastasis. Journal of Cancer Metastasis and Treatment. 5. PMID 32395618 DOI: 10.20517/2394-4722.2019.24 |
0.38 |
|
| 2019 |
Seachrist DD, Keri RA. The Activin Social Network: Activin, Inhibin and Follistatin in Breast Development and Cancer. Endocrinology. PMID 30874767 DOI: 10.1210/En.2019-00015 |
0.434 |
|
| 2019 |
Thakur V, Zhang K, Savadelis A, Zmina P, Aguila B, Welford SM, Abdul-Karim F, Bonk KW, Keri RA, Bedogni B. The membrane tethered matrix metalloproteinase MT1-MMP triggers an outside-in DNA damage response that impacts chemo- and radiotherapy responses of breast cancer. Cancer Letters. 443: 115-124. PMID 30502358 DOI: 10.1016/J.Canlet.2018.11.031 |
0.488 |
|
| 2019 |
Shively, Gayle S, Sahni J, Keri R. Abstract P5-03-01: LIN9 regulation of NEK2 underlies taxol resistance in triple-negative breast cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P5-03-01 |
0.546 |
|
| 2019 |
Webb B, Sahni J, Keri R. Abstract P4-07-06: Cyclin dependent kinase 7 (CDK7) inhibition with THZ1 induces mitotic failure and increases genomic instability in triple negative breast cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P4-07-06 |
0.581 |
|
| 2019 |
Ingles NN, Seachrist D, Keri R. Abstract 172: BCL11A regulation of extracellular matrix genes may be necessary for invasion of triple-negative breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-172 |
0.514 |
|
| 2018 |
Gayle SS, Sahni JM, Webb BM, Weber-Bonk KL, Shively MS, Spina R, Bar EE, Summers MK, Keri RA. Targeting BCL-xL improves the efficacy of bromodomain and extra-terminal protein inhibitors in triple-negative breast cancer by eliciting the death of senescent cells. The Journal of Biological Chemistry. PMID 30482844 DOI: 10.1074/Jbc.Ra118.004712 |
0.485 |
|
| 2018 |
Hashemi-Sadraei N, Müller-Greven GM, Abdul-Karim FW, Ulasov I, Downs-Kelly E, Burgett ME, Lauko A, Qadan MA, Weil RJ, Ahluwalia MS, Du L, Prayson RA, Chao ST, Budd TG, Barnholtz-Sloan J, ... ... Keri RA, et al. Expression of LC3B and FIP200/Atg17 in brain metastases of breast cancer. Journal of Neuro-Oncology. PMID 30094720 DOI: 10.1007/S11060-018-2959-5 |
0.559 |
|
| 2018 |
Tsung K, Thompson CL, Knight JM, Maximuk S, Sadri N, Gilmore H, Keri RA, Vinayak S, Harris L, Silverman P. A breast multi-disciplinary genomic tumor board is feasible and can provide timely and impactful recommendations. The Breast Journal. PMID 29517142 DOI: 10.1111/Tbj.13027 |
0.457 |
|
| 2018 |
Yang X, Pan Y, Qiu Z, Du Z, Zhang Y, Fa P, Gorityala S, Ma S, Li S, Chen C, Wang H, Xu Y, Yan C, Keri RA, Ma Z, et al. RNF126 as a biomarker of a poor prognosis in invasive breast cancer and CHK1 inhibitor efficacy in breast cancer cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29326282 DOI: 10.1158/1078-0432.Ccr-17-2242 |
0.511 |
|
| 2018 |
Seachrist DD, Ingles NN, Hannigan MM, Licatalosi DD, Keri RA. Abstract 32: BCL11A is necessary for the expression of extracellular matrix genes and metastatic progression of triple-negative breast cancer Cancer Research. 78: 32-32. DOI: 10.1158/1538-7445.Am2018-32 |
0.533 |
|
| 2018 |
Liao P, Yori J, Keri R, Koyuturk M, Barnholtz-Sloan J. Abstract 2262: Inference of kinase activity for cancer phosphoproteomics using substrate prediction scores Cancer Research. 78: 2262-2262. DOI: 10.1158/1538-7445.Am2018-2262 |
0.779 |
|
| 2017 |
Sahni JM, Keri RA. Targeting bromodomain and extraterminal proteins in breast cancer. Pharmacological Research. PMID 29154989 DOI: 10.1016/J.Phrs.2017.11.015 |
0.604 |
|
| 2017 |
Sahni JM, Gayle SS, Webb B, Weber-Bonk KL, Seachrist DD, Singh S, Sizemore ST, Restrepo NA, Bebek G, Scacheri P, Varadan V, Summers MK, Keri RA. Mitotic vulnerability in triple-negative breast cancer associated with LIN9 is targetable with BET inhibitors. Cancer Research. PMID 28807940 DOI: 10.1158/0008-5472.Can-17-1571 |
0.585 |
|
| 2017 |
Morrison CD, Chang JC, Keri RA, Schiemann WP. Mutant p53 dictates the oncogenic activity of c-Abl in triple-negative breast cancers. Cell Death & Disease. 8: e2899. PMID 28661474 DOI: 10.1038/Cddis.2017.294 |
0.507 |
|
| 2017 |
Seachrist DD, Sizemore ST, Johnson E, Abdul-Karim FW, Weber Bonk KL, Keri RA. Follistatin is a metastasis suppressor in a mouse model of HER2-positive breast cancer. Breast Cancer Research : Bcr. 19: 66. PMID 28583174 DOI: 10.1186/S13058-017-0857-Y |
0.561 |
|
| 2017 |
Cohen AJ, Saiakhova A, Corradin O, Luppino JM, Lovrenert K, Bartels CF, Morrow JJ, Mack SC, Dhillon G, Beard L, Myeroff L, Kalady MF, Willis J, Bradner JE, Keri RA, et al. Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome. Nature Communications. 8: 14400. PMID 28169291 DOI: 10.1038/Ncomms14400 |
0.335 |
|
| 2016 |
Sahni JM, Gayle SS, Weber-Bonk KL, Cuellar Vite L, Yori JL, Webb B, Ramos EK, Seachrist DD, Landis MD, Chang JC, Bradner JE, Keri RA. Bromodomain and extraterminal protein inhibition blocks growth of triple-negative breast cancers through the suppression of Aurora kinases. The Journal of Biological Chemistry. PMID 27650498 DOI: 10.1074/Jbc.M116.738666 |
0.814 |
|
| 2016 |
Morrison CD, Allington TM, Thompson CL, Gilmore HL, Chang JC, Keri RA, Schiemann WP. c-Abl inhibits breast cancer tumorigenesis through reactivation of p53-mediated p21 expression. Oncotarget. PMID 27626309 DOI: 10.18632/Oncotarget.11909 |
0.472 |
|
| 2016 |
Brancato JM, Gayle S, Weber-Bonk K, Summers M, Bebek G, Keri R. Abstract 4647: BET protein inhibition blocks growth of triple-negative breast cancer by inducing mitotic and cytokinetic dysfunction Cancer Research. 76: 4647-4647. DOI: 10.1158/1538-7445.Am2016-4647 |
0.605 |
|
| 2015 |
Yehia L, Niazi F, Ni Y, Ngeow J, Sankunny M, Liu Z, Wei W, Mester JL, Keri RA, Zhang B, Eng C. Germline Heterozygous Variants in SEC23B Are Associated with Cowden Syndrome and Enriched in Apparently Sporadic Thyroid Cancer. American Journal of Human Genetics. 97: 661-676. PMID 26522472 DOI: 10.1016/J.Ajhg.2015.10.001 |
0.453 |
|
| 2015 |
Seachrist DD, Bonk KW, Ho SM, Prins GS, Soto AM, Keri RA. A review of the carcinogenic potential of bisphenol A. Reproductive Toxicology (Elmsford, N.Y.). PMID 26493093 DOI: 10.1016/J.Reprotox.2015.09.006 |
0.38 |
|
| 2014 |
Yori JL, Lozada KL, Seachrist DD, Mosley JD, Abdul-Karim FW, Booth CN, Flask CA, Keri RA. Combined SFK/mTOR inhibition prevents rapamycin-induced feedback activation of AKT and elicits efficient tumor regression. Cancer Research. 74: 4762-71. PMID 25023728 DOI: 10.1158/0008-5472.Can-13-3627 |
0.832 |
|
| 2014 |
Sizemore GM, Sizemore ST, Seachrist DD, Keri RA. GABA(A) receptor pi (GABRP) stimulates basal-like breast cancer cell migration through activation of extracellular-regulated kinase 1/2 (ERK1/2). The Journal of Biological Chemistry. 289: 24102-13. PMID 25012653 DOI: 10.1074/Jbc.M114.593582 |
0.596 |
|
| 2014 |
Sizemore ST, Sizemore GM, Booth CN, Thompson CL, Silverman P, Bebek G, Abdul-Karim FW, Avril S, Keri RA. Hypomethylation of the MMP7 promoter and increased expression of MMP7 distinguishes the basal-like breast cancer subtype from other triple-negative tumors. Breast Cancer Research and Treatment. 146: 25-40. PMID 24847890 DOI: 10.1007/S10549-014-2989-4 |
0.52 |
|
| 2014 |
Peiris PM, Tam M, Vicente P, Abramowski A, Toy R, Bauer L, Mayer A, Pansky J, Doolittle E, Tucci S, Schmidt E, Shoup C, Rao S, Murray K, Gopalakrishnan R, ... Keri RA, et al. On-command drug release from nanochains inhibits growth of breast tumors. Pharmaceutical Research. 31: 1460-8. PMID 23934254 DOI: 10.1007/S11095-013-1102-8 |
0.479 |
|
| 2013 |
Sizemore GM, Sizemore ST, Pal B, Booth CN, Seachrist DD, Abdul-Karim FW, Kume T, Keri RA. FOXC1 is enriched in the mammary luminal progenitor population, but is not necessary for mouse mammary ductal morphogenesis. Biology of Reproduction. 89: 10. PMID 23677979 DOI: 10.1095/Biolreprod.113.108001 |
0.552 |
|
| 2013 |
Asrani K, Keri RA, Galisteo R, Brown SA, Morgan SJ, Ghosh A, Tran NL, Winkles JA. The HER2- and heregulin β1 (HRG)-inducible TNFR superfamily member Fn14 promotes HRG-driven breast cancer cell migration, invasion, and MMP9 expression. Molecular Cancer Research : McR. 11: 393-404. PMID 23378579 DOI: 10.1158/1541-7786.Mcr-12-0542 |
0.604 |
|
| 2013 |
Bernardo GM, Bebek G, Ginther CL, Sizemore ST, Lozada KL, Miedler JD, Anderson LA, Godwin AK, Abdul-Karim FW, Slamon DJ, Keri RA. FOXA1 represses the molecular phenotype of basal breast cancer cells. Oncogene. 32: 554-63. PMID 22391567 DOI: 10.1038/Onc.2012.62 |
0.577 |
|
| 2013 |
Yori JL, Lozada K, Seachrist DD, Mosley J, Abdul-Karim FW, Booth CN, Flask CA, Keri RA. Abstract LB-221: Inhibition of rapamycin-induced feedback activation of AKT with dasatinib induces complete tumor regression in a preclinical model of breast cancer. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-221 |
0.837 |
|
| 2012 |
Peiris PM, Toy R, Doolittle E, Pansky J, Abramowski A, Tam M, Vicente P, Tran E, Hayden E, Camann A, Mayer A, Erokwu BO, Berman Z, Wilson D, Baskaran H, ... ... Keri RA, et al. Imaging metastasis using an integrin-targeting chain-shaped nanoparticle. Acs Nano. 6: 8783-95. PMID 23005348 DOI: 10.1021/Nn303833P |
0.325 |
|
| 2012 |
Seachrist DD, Johnson E, Magee C, Clay CM, Graham JK, Veeramachaneni DN, Keri RA. Overexpression of follistatin in the mouse epididymis disrupts fluid resorption and sperm transit in testicular excurrent ducts. Biology of Reproduction. 87: 41. PMID 22649074 DOI: 10.1095/Biolreprod.111.097527 |
0.347 |
|
| 2012 |
Sizemore ST, Keri RA. The forkhead box transcription factor FOXC1 promotes breast cancer invasion by inducing matrix metalloprotease 7 (MMP7) expression. The Journal of Biological Chemistry. 287: 24631-40. PMID 22645147 DOI: 10.1074/Jbc.M112.375865 |
0.53 |
|
| 2012 |
Peiris PM, Bauer L, Toy R, Tran E, Pansky J, Doolittle E, Schmidt E, Hayden E, Mayer A, Keri RA, Griswold MA, Karathanasis E. Enhanced delivery of chemotherapy to tumors using a multicomponent nanochain with radio-frequency-tunable drug release. Acs Nano. 6: 4157-68. PMID 22486623 DOI: 10.1021/Nn300652P |
0.316 |
|
| 2012 |
Bernardo GM, Keri RA. FOXA1: a transcription factor with parallel functions in development and cancer. Bioscience Reports. 32: 113-30. PMID 22115363 DOI: 10.1042/Bsr20110046 |
0.446 |
|
| 2011 |
Beach JR, Hussey GS, Miller TE, Chaudhury A, Patel P, Monslow J, Zheng Q, Keri RA, Reizes O, Bresnick AR, Howe PH, Egelhoff TT. Myosin II isoform switching mediates invasiveness after TGF-β-induced epithelial-mesenchymal transition. Proceedings of the National Academy of Sciences of the United States of America. 108: 17991-6. PMID 22025714 DOI: 10.1073/Pnas.1106499108 |
0.341 |
|
| 2011 |
Yori JL, Seachrist DD, Johnson E, Lozada KL, Abdul-Karim FW, Chodosh LA, Schiemann WP, Keri RA. Krüppel-like factor 4 inhibits tumorigenic progression and metastasis in a mouse model of breast cancer. Neoplasia (New York, N.Y.). 13: 601-10. PMID 21750654 DOI: 10.1593/Neo.11260 |
0.841 |
|
| 2011 |
Weber Lozada K, Keri RA. Bisphenol A increases mammary cancer risk in two distinct mouse models of breast cancer. Biology of Reproduction. 85: 490-7. PMID 21636739 DOI: 10.1095/Biolreprod.110.090431 |
0.561 |
|
| 2010 |
Montañez-Wiscovich ME, Shelton MD, Seachrist DD, Lozada KL, Johnson E, Miedler JD, Abdul-Karim FW, Visvader JE, Keri RA. Aberrant expression of LMO4 induces centrosome amplification and mitotic spindle abnormalities in breast cancer cells. The Journal of Pathology. 222: 271-81. PMID 20814902 DOI: 10.1002/Path.2762 |
0.561 |
|
| 2010 |
Johnson E, Seachrist DD, DeLeon-Rodriguez CM, Lozada KL, Miedler J, Abdul-Karim FW, Keri RA. HER2/ErbB2-induced breast cancer cell migration and invasion require p120 catenin activation of Rac1 and Cdc42. The Journal of Biological Chemistry. 285: 29491-501. PMID 20595387 DOI: 10.1074/Jbc.M110.136770 |
0.587 |
|
| 2010 |
Bernardo GM, Lozada KL, Miedler JD, Harburg G, Hewitt SC, Mosley JD, Godwin AK, Korach KS, Visvader JE, Kaestner KH, Abdul-Karim FW, Montano MM, Keri RA. FOXA1 is an essential determinant of ERalpha expression and mammary ductal morphogenesis. Development (Cambridge, England). 137: 2045-54. PMID 20501593 DOI: 10.1242/Dev.043299 |
0.588 |
|
| 2010 |
Yori JL, Johnson E, Zhou G, Jain MK, Keri RA. Kruppel-like factor 4 inhibits epithelial-to-mesenchymal transition through regulation of E-cadherin gene expression. The Journal of Biological Chemistry. 285: 16854-63. PMID 20356845 DOI: 10.1074/Jbc.M110.114546 |
0.803 |
|
| 2010 |
Lozada KW, Keri RA. Bisphenol A Increases Mammary Cancer Risk in Multiple Murine Models of Breast Cancer. Biology of Reproduction. 83: 75-75. DOI: 10.1093/Biolreprod/83.S1.75 |
0.538 |
|
| 2009 |
Montañez-Wiscovich ME, Seachrist DD, Landis MD, Visvader J, Andersen B, Keri RA. LMO4 is an essential mediator of ErbB2/HER2/Neu-induced breast cancer cell cycle progression. Oncogene. 28: 3608-18. PMID 19648968 DOI: 10.1038/Onc.2009.221 |
0.821 |
|
| 2009 |
Mosley JD, Keri RA. Intrinsic bias in breast cancer gene expression data sets Bmc Cancer. 9. PMID 19563679 DOI: 10.1186/1471-2407-9-214 |
0.444 |
|
| 2009 |
Peters GA, Seachrist DD, Keri RA, Sen GC. The double-stranded RNA-binding protein, PACT, is required for postnatal anterior pituitary proliferation. Proceedings of the National Academy of Sciences of the United States of America. 106: 10696-701. PMID 19541653 DOI: 10.1073/Pnas.0900735106 |
0.35 |
|
| 2008 |
Mosley JD, Keri RA. Cell cycle correlated genes dictate the prognostic power of breast cancer gene lists. Bmc Medical Genomics. 1: 11. PMID 18439262 DOI: 10.1186/1755-8794-1-11 |
0.376 |
|
| 2008 |
Milliken EL, Lozada KL, Johnson E, Landis MD, Seachrist DD, Whitten I, Sutton AL, Abdul-Karim FW, Keri RA. Ovarian hyperstimulation induces centrosome amplification and aneuploid mammary tumors independently of alterations in p53 in a transgenic mouse model of breast cancer. Oncogene. 27: 1759-66. PMID 17891171 DOI: 10.1038/Sj.Onc.1210815 |
0.823 |
|
| 2007 |
Sutton AL, Keri RA. The pleiotropic effects of excessive luteinizing hormone secretion in transgenic mice. Seminars in Reproductive Medicine. 25: 360-7. PMID 17710732 DOI: 10.1055/S-2007-984742 |
0.335 |
|
| 2007 |
Mosley JD, Poirier JT, Seachrist DD, Landis MD, Keri RA. Rapamycin inhibits multiple stages of c-Neu/ErbB2 induced tumor progression in a transgenic mouse model of HER2-positive breast cancer. Molecular Cancer Therapeutics. 6: 2188-97. PMID 17699716 DOI: 10.1158/1535-7163.Mct-07-0235 |
0.818 |
|
| 2007 |
Casadesus G, Milliken EL, Webber KM, Bowen RL, Lei Z, Rao CV, Perry G, Keri RA, Smith MA. Increases in luteinizing hormone are associated with declines in cognitive performance. Molecular and Cellular Endocrinology. 269: 107-11. PMID 17376589 DOI: 10.1016/J.Mce.2006.06.013 |
0.749 |
|
| 2006 |
Mosley JD, Keri RA. Splice variants of mIAP1 have an enhanced ability to inhibit apoptosis Biochemical and Biophysical Research Communications. 348: 1174-1183. PMID 16905118 DOI: 10.1016/J.Bbrc.2006.07.176 |
0.32 |
|
| 2006 |
Landis MD, Seachrist DD, Abdul-Karim FW, Keri RA. Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors. Oncogene. 25: 3325-34. PMID 16434967 DOI: 10.1038/Sj.Onc.1209365 |
0.767 |
|
| 2005 |
Milliken EL, Zhang X, Flask C, Duerk JL, MacDonald PN, Keri RA. EB1089, a vitamin D receptor agonist, reduces proliferation and decreases tumor growth rate in a mouse model of hormone-induced mammary cancer. Cancer Letters. 229: 205-15. PMID 16115727 DOI: 10.1016/J.Canlet.2005.06.044 |
0.838 |
|
| 2005 |
Landis MD, Seachrist DD, Montañez-Wiscovich ME, Danielpour D, Keri RA. Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-beta signaling in ErbB2/Neu-induced tumors from transgenic mice. Oncogene. 24: 5173-90. PMID 15897883 DOI: 10.1038/Sj.Onc.1208712 |
0.761 |
|
| 2004 |
Knostman KA, Cho JY, Ryu KY, Lin X, McCubrey JA, Hla T, Liu CH, Di Carlo E, Keri R, Zhang M, Hwang DY, Kisseberth WC, Capen CC, Jhiang SM. Signaling through 3',5'-cyclic adenosine monophosphate and phosphoinositide-3 kinase induces sodium/iodide symporter expression in breast cancer. The Journal of Clinical Endocrinology and Metabolism. 89: 5196-203. PMID 15472226 DOI: 10.1210/Jc.2004-0907 |
0.549 |
|
| 2003 |
Mann RJ, Keri RA, Nilson JH. Consequences of elevated luteinizing hormone on diverse physiological systems: use of the LHbetaCTP transgenic mouse as a model of ovarian hyperstimulation-induced pathophysiology. Recent Progress in Hormone Research. 58: 343-75. PMID 12795427 DOI: 10.1210/Rp.58.1.343 |
0.466 |
|
| 2003 |
Mikola M, Kero J, Nilson JH, Keri RA, Poutanen M, Huhtaniemi I. High levels of luteinizing hormone analog stimulate gonadal and adrenal tumorigenesis in mice transgenic for the mouse inhibin-alpha-subunit promoter/Simian virus 40 T-antigen fusion gene. Oncogene. 22: 3269-78. PMID 12761497 DOI: 10.1038/Sj.Onc.1206518 |
0.394 |
|
| 2002 |
Milliken EL, Ameduri RK, Landis MD, Behrooz A, Abdul-Karim FW, Keri RA. Ovarian hyperstimulation by LH leads to mammary gland hyperplasia and cancer predisposition in transgenic mice. Endocrinology. 143: 3671-80. PMID 12193583 DOI: 10.1210/En.2002-220228 |
0.822 |
|
| 2002 |
Owens GE, Keri RA, Nilson JH. Ovulatory surges of human CG prevent hormone-induced granulosa cell tumor formation leading to the identification of tumor-associated changes in the transcriptome. Molecular Endocrinology (Baltimore, Md.). 16: 1230-42. PMID 12040011 DOI: 10.1210/Mend.16.6.0850 |
0.431 |
|
| 2001 |
Quirk CC, Lozada KL, Keri RA, Nilson JH. A single Pitx1 binding site is essential for activity of the LHbeta promoter in transgenic mice. Molecular Endocrinology (Baltimore, Md.). 15: 734-46. PMID 11328855 DOI: 10.1210/Mend.15.5.0628 |
0.328 |
|
| 2000 |
Keri RA, Bachmann DJ, Behrooz A, Herr BD, Ameduri RK, Quirk CC, Nilson JH. An NF-Y binding site is important for basal, but not gonadotropin-releasing hormone-stimulated, expression of the luteinizing hormone beta subunit gene. The Journal of Biological Chemistry. 275: 13082-8. PMID 10777613 DOI: 10.1074/Jbc.275.17.13082 |
0.343 |
|
| 2000 |
Kero J, Poutanen M, Zhang FP, Rahman N, McNicol AM, Nilson JH, Keri RA, Huhtaniemi IT. Elevated luteinizing hormone induces expression of its receptor and promotes steroidogenesis in the adrenal cortex. The Journal of Clinical Investigation. 105: 633-41. PMID 10712435 DOI: 10.1172/Jci7716 |
0.349 |
|
| 2000 |
Keri RA, Lozada KL, Abdul-Karim FW, Nadeau JH, Nilson JH. Luteinizing hormone induction of ovarian tumors: oligogenic differences between mouse strains dictates tumor disposition. Proceedings of the National Academy of Sciences of the United States of America. 97: 383-7. PMID 10618427 DOI: 10.1073/Pnas.97.1.383 |
0.427 |
|
| 1997 |
Farmerie TA, Abbud RA, Budworth PR, Clay CM, Keri RA, McDowell KJ, Wolfe MW, Nilson JH. Characterization of the equine glycoprotein hormone alpha-subunit gene reveals divergence in the mechanism of pituitary and placental expression. Biology of Reproduction. 57: 1104-14. PMID 9369177 DOI: 10.1095/Biolreprod57.5.1104 |
0.308 |
|
| 1994 |
Keri RA, Wolfe MW, Saunders TL, Anderson I, Kendall SK, Wagner T, Yeung J, Gorski J, Nett TM, Camper SA. The proximal promoter of the bovine luteinizing hormone beta-subunit gene confers gonadotrope-specific expression and regulation by gonadotropin-releasing hormone, testosterone, and 17 beta-estradiol in transgenic mice. Molecular Endocrinology (Baltimore, Md.). 8: 1807-16. PMID 7708066 DOI: 10.1210/Mend.8.12.7708066 |
0.307 |
|
| 1991 |
Keri RA, Andersen B, Kennedy GC, Hamernik DL, Clay CM, Brace AD, Nett TM, Notides AC, Nilson JH. Estradiol inhibits transcription of the human glycoprotein hormone alpha-subunit gene despite the absence of a high affinity binding site for estrogen receptor. Molecular Endocrinology (Baltimore, Md.). 5: 725-33. PMID 1712910 DOI: 10.1210/Mend-5-5-725 |
0.302 |
|
| 1991 |
Kendall SK, Saunders TL, Jin L, Lloyd RV, Glode LM, Nett TM, Keri RA, Nilson JH, Camper SA. Targeted ablation of pituitary gonadotropes in transgenic mice. Molecular Endocrinology (Baltimore, Md.). 5: 2025-36. PMID 1665205 DOI: 10.1210/Mend-5-12-2025 |
0.335 |
|
| Show low-probability matches. |